Objectives. Glucocorticoids (GCs) are a mainstay of treatment for patients with ANCA-associated vasculitis (AAV) but are associated with significant adverse effects. Effective remission induction in severe AAV using extremely limited GC exposure has not been attempted. We tested an early rapid GC withdrawal induction regimen for patients with severe AAV.
Introduction
Survival in patients with ANCA-associated vasculitis (AAV) has improved since the introduction of CYC-and glucocorticoid (GC)-based treatment regimens [13] . However, patients within the first year of diagnosis are at greater risk of death from adverse events rather than active vasculitis. Important drivers of early mortality include infection and leucopoenia, with both renal impairment and older age being significant predictors of these adverse events [4] . In an attempt to reduce this early morbidity, treatment regimens have been refined in the belief that limiting CYC exposure would have a positive impact on outcomes. However, despite minimizing, or completely substituting, CYC with rituximab (RTX) in induction regimens, no difference in adverse events has been found [5, 6] . In RTXbased trials, conventional dosing of i.v. and oral GCs was mandated for the induction of disease remission. However, GC tapering has been used successfully in combination with RTX alone [7] or with combined RTX and low-dose CYC [8, 9] in cohort studies of patients with mild and moderate renal involvement, respectively. With RTX alone, reduced adverse effects but greater relapse rates were found [7] , while combined CYC and RTX resulted in both fewer relapses and adverse events [8, 9] . These data suggest that total GC exposure plays a major role in mediating serious adverse events. In addition to infectious risks, prolonged high-dose GC use is responsible for osteoporosis [10] , weight gain, cataracts [11] , hyperglycaemia and diabetes [12] and cardiovascular events [13] , with a clear relationship between adverse events, as well as cumulative damage, assessed by the Vasculitis Damage Index (VDI) and extent of GC exposure [11, 14] . This problem is not limited to AAV, as GCs are used ubiquitously in the management of autoimmune rheumatologic diseases; in patients with RA, GC use is associated with a dose-dependent increase in mortality with a threshold daily dose of 8 mg [15] , while both the dose and cumulative exposure to GC result in an increased risk of myocardial infarction [16] . In LN, lower GC doses were associated with fewer serious adverse events [17] . Until the recent PEXIVAS (plasma exchange and glucocorticoid dosing in the treatment of AAV) trial, the dose and taper of GCs during induction treatment in AAV has not been subjected to analysis, with previous trials all using high-dose GCs alongside cytotoxic or biologic agents [5, 18, 19] .
Beyond induction therapy, the use of maintenance GC to prevent relapse is controversial but frequently employed. A meta-analysis suggested that patients in trials with a non-zero GC endpoint suffered fewer relapses compared with those enrolled in trials with a predefined GC withdrawal [20] . In contrast, others have shown that the use of GC therapy beyond 6 months from diagnosis is associated with an increased risk of infections but no reduction in relapse [21] .
Early GC withdrawal or avoidance has been successfully introduced in renal transplantation [22, 23] and reported in the treatment of LN [24] . More recently, in AAV, a phase 2 induction trial demonstrated that the use of Avacopan, a C5a receptor inhibitor, was effective in replacing high-dose GC alongside CYC or RTX [25] in patients with milder AAV disease followed for just 12 weeks.
We report the outcome of two separate cohorts of AAV patients with acute and severe disease treated with similar GC-sparing regimens, based on combined use of RTX and low-dose i.v. CYC, which achieved excellent outcomes, comparable to standard GC-based regimens.
Methods

Patients
Two prospective groups of patients were included with minor differences in the duration of oral GCs: group 1 was treated at Imperial College Healthcare NHS Trust and group 2 was treated at the Royal Free Hospital and Trinity Health Kidney Centre, Dublin, Ireland. Patients were included with either a new diagnosis of AAV or with relapsing disease. The diagnosis was made based on a combination of relevant clinical features and positive PR3-ANCA or MPO-ANCA serology. ANCA-negative patients with crescentic pauci-immune glomerulonephritis were included and considered to have renal-limited vasculitis. Group 1 excluded but group 2 included patients with severe disease, requiring dialysis or with alveolar haemorrhage. However, patients with an anti-glomerular basement membrane antibody and those on long-term GC therapy were excluded. In view of the national variation in GC use, this protocol change to the previously published RITUXIVAS trial was felt not to require formal ethical approval.
Groups 1 and 2 were exposed to slightly different treatment regimens (Table 1) . Both were based on a short course of prednisolone, with all patients in group 1 and 65% of patients in group 2 receiving i.v. methylprednisolone alongside low-dose CYC and two 1 g doses of RTX. Group 1 was treated with a total of 7 days of oral prednisolone, while group 2 was treated for 14 days. Those presenting with dialysis-dependent renal failure were considered for plasma exchange.
Following six doses of CYC, maintenance treatment was commenced with AZA or, if intolerant, MMF, MTX or RTX. The dose of AZA was 2 mg/kg (maximum 150 mg), or 1 mg/kg in those with reduced thiopurine methyltransferase levels. All patients were treated with co-trimoxazole for 3 months, gastric protection with a proton pump inhibitor and bone protection with calcium/ vitamin D combinations. Patients from high-risk groups were also given prophylaxis against tuberculosis with isoniazid and pyridoxine.
Comparison with European Vasculitis Society (EUVAS) trial patients
Patients were matched based on age, baseline estimated glomerular filtration rate, chronic kidney disease staging criteria and ANCA specificity with patients (n = 139) from three EUVAS clinical trials (CYCAZAREM [26] , CYCLOPS [19, 27] and MEPEX [18] ) in a ratio of 3:1 for casecontrol analysis. A separate comparison was made with the RTX group from the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial [6, 28] , which used a comparable CYC-and RTX-based regimen but with standard GC dosing.
Clinical assessment
We recorded the following parameters at baseline and months 1, 3, 6 and 12: BVAS (version 3), serum creatinine (mmol/l), urine protein:creatinine ratio (uPCR; mg/mmol) and ANCA titre (IU/ml). B cells were considered depleted if the peripheral CD19 cell count was 410 cells/ml. Additionally, we recorded potential GC-related adverse effects, including the incidence of new-onset diabetes, weight gain and infectious complications. Severe infections were defined as those requiring i.v. antibiotics and/or hospital admission.
Statistical analysis
Where three or more groups were analysed, non-parametric one-way analysis of variance using the KruskalWallis test was applied. P-values <0.05 were considered significant. ANCA-negative patients were considered MPO-ANCA positive for the purpose of casecontrol matching. Continuous variables are expressed as means with 95% CIs or medians with 25th75th quartiles. Categorical variables are presented as percentages and frequencies. 
Results
Baseline characteristics
The demographic features and baseline clinical characteristics are summarized in Table 2 . There were 23 patients in group 1 and 26 in group 2, all except 3 (who died after 7 and 9 months) with at least 12 months of follow-up. Both groups included PR3-or MPO-ANCA-positive patients, and a limited number (n = 3) of ANCA-negative patients. A total of 44/49 (90%) patients had a new presentation of AAV, while the remainder had relapsing disease. All except one had renal involvement, which was biopsy proven in 44/49 patients (90%). In those not biopsied, glomerulonephritis was inferred from deteriorating renal function in association with new urinary abnormalities. Four patients (8%) presented with pulmonary haemorrhage and three (6%) were dialysis dependent at enrolment.
Treatment
Group 1 (n = 23)
All patients received 2 Â 1 g doses of RTX. Twenty-one (91%) patients received concomitant CYC; in two patients with relapsing disease, CYC was withheld due to concerns about cumulative prior exposure. Deviations from GC dose protocol resulted from variations in steroid use at other units prior to referral. The median dose of i.v. methylprednisolone and oral prednisolone was 750 mg (range 04000) and 210 mg (range 01155), respectively. The maximum duration of GC treatment was 3 weeks. During the first year of follow-up, four patients required the introduction of GC treatment after the initial protocol treatment for symptoms of active vasculitis (myalgia, fatigue or pleuro-pericarditis; n = 2), while the two others were for non-vasculitic reasons, including treatment of severe palmoplantar psoriasis and development of AZAinduced interstitial pneumonitis.
Group 2 (n = 26) All patients received 2 Â 1 g doses of RTX (except one who received 0.6 g). All received CYC, with the exception of one patient presenting with extrarenal relapse. A total of 17/26 (65%) patients were treated with i.v. methylprednisolone [median dose 500 mg (range 1251500)]. All 26 patients were treated with prednisolone. The median total cumulative dose of oral prednisolone was 735 mg (range 2801800) and the median duration of prednisolone treatment was 15 days (range 10142). Combining the methylprednisolone and prednisolone exposure, the total median dose of GC exposure was 1235 mg (range Table 2 .
Response to treatment and outcomes In all patients there was an improvement in BVAS by month 1 (Fig. 1A) . This was sustained in the two groups over 12 months ]group 1: baseline vs all subsequent time points (P < 0.0001); group 2: baseline vs all subsequent time points (P < 0.0001)] (Table 3) . Similarly, there was a decrease in CRP from month 1 onwards (Fig. 1B) [group 1: baseline vs month 1 (P < 0.05), vs month 3 (P < 0.001), vs month 6 (P < 0.01), vs month 12 (P < 0.01); group 2: baseline vs month 3 and subsequent time points (P < 0.0001)] (Table 3) . At 6 months, 47/49 patients (96%) were in disease remission without additional GC. Both patients from group 1 that required reintroduction of GC at weeks 4 and 6 for symptoms of active vasculitis achieved remission by month 6. At 12 months, 44/49 patients (90%) had a sustained remission without addition of further GC (there were three deaths at months 7, 9 and 9 and two relapses at months 7 and 12).
Kidney function in both groups improved by 3 months and was sustained in 47/49 patients at 12 months (two patients had renal relapse at months 7 and 12 resulting in the loss of renal function) (Fig. 1C and Table 3 ). The median creatinine at the time of entry was 179 mmol/l (range 62469) and 174 mmol/l (range 89999) and at month 12 it was 109 mmol/l (range 64423) and 113 mmol/l (range 64216) in groups 1 and 2, respectively (Table 3) . In both groups, the decreases in creatinine were statistically significant [group 1: baseline vs month 12 (P < 0.05); group 2: baseline vs month 3 (P < 0.05), vs month 6 (P < 0.01) and vs month 12 (P < 0.001)].
There were similar reductions in proteinuria (uPCR) from month 3 onwards (Table 3 and Fig. 1D ). The median uPCR at the time of entry was 140 mg/mmol (range 421150) and 197 mg/mmol (range 11611), decreasing to 33 mg/mmol (range 0533) and 32 mg/mmol (range 0476) at month 12 in groups 1 and 2, respectively. In both groups the reduction in proteinuria was significant from baseline to month 3 (group 1, P < 0.05; group 2, P < 0.001), month 6 (group 1, https://academic.oup.com/rheumatology P < 0.01; group 2, P < 0.0001) and month 12 (group 1, P < 0.05; group 2, P < 0.0001). All three patients in group 2 who initially required dialysis became dialysis independent after 11, 36 and 53 days and had a median 12 month creatinine of 132 mmol/l (range 95133) and a median uPCR of 34 mg/mmol (range 2064) at month 6. The patient requiring dialysis for 53 days also received seven plasma exchange sessions. During follow-up, no patient returned to dialysis or developed end-stage renal failure.
A VDI was calculated for all the patients at 12 months. In both groups the median VDI was 1 with ranges 03 and 05 in groups 1 and 2, respectively.
B cells and ANCA
All patients achieved B cell depletion by 13 months (missing data on one patient in both groups). At 6 months, five patients in group 1 and three in group 2 had B cells >10 cells/ml. Both groups demonstrated a significant (F) Changes in CD19 counts in individual patients (black line group 1, grey line group 2). *P < 0.05, **P < 0.01 and *** P < 0.001. IQR: interquartile range. reduction in ANCA levels from baseline to month 3 (group 1, P < 0.05; group 2, P < 0.01), month 6 (group 1, P < 0.01; group 2, P < 0.001) and month 12 (group 1, P < 0.01; group 2, P < 0.0001). Eleven patients in both groups became ANCA negative at 12 months.
Relapse
Two patients (9%) in group 1 and one (4%) in group 2 experienced disease relapse. One (who had required reintroduction of GC at week 6) experienced multisystem flare at 7 months, which was treated with RTX and oral GC, with resultant sustained remission until 12 months. One, with relapsing PR3-AAV, had a further relapse at 12 months, successfully treated with RTX and CYC without the addition of GC. One patient in group 2 had an extrarenal relapse at month 8 in the context of B cell reconstitution and positive PR3-ANCA.
Adverse events
The data for adverse events are summarized in Table 4 . There were two deaths in group 1 (one at month 9 as a complication of bronchoscopy; one sudden cardiac death at month 9) and one in group 2 (at month 7 from fungal pneumonia). There were no new cases of diabetes. There was one hip fracture, but this patient had received no long-term maintenance steroids. A total of five patients developed severe infections (three in group 1, two in group 2). In group 1 there were four severe respiratory infections in three patients, all of whom had pre-existing airway disease. In group 2, one patient who had a prolonged course of steroids due to disease activity All values presented as median (range).
https://academic.oup.com/rheumatology developed recurrent sepsis and received numerous courses of i.v. antibiotics.
Comparison with GC-treated trial patients
The cases included in this study were compared with patient data from previous EUVAS trials that are summarized in Table 5 . The patients in this study received less GC and CYC therapy (P < 0.001 for each) than historic controls but achieved similar rates of remission, with similar improvements in renal function and reductions in BVAS. There were no new cases of diabetes at 1 year, compared with 8.2% in the EUVAS studies. Importantly, we found fewer severe infections requiring hospitalization or i.v. antibiotics in our cases (12.2%) compared with those induced with the RTX/CYC regimen used in RITUXVAS (30%; P = 0.02) in which the median CYC dose was 1720 mg (range 9802265).
Discussion
This study reports a novel extreme GC minimization regimen for patients with severe AAV, with high remission rates and good patient outcomes. It suggests that rapid GC withdrawal, within 2 weeks, when used in conjunction with an RTX/CYC-based induction regimen is feasible. A previous study demonstrated that a regimen of RTX with low-dose CYC and standard-dose prednisolone is a safe and effective treatment in patients with severe AAV not requiring dialysis [8, 9] , while RTX and 8 weeks of GC is also effective in patients with mild disease [7] . It should be noted that despite minor differences in the GC component of the protocols between the two groups, the outcomes were similar. This suggests that lower doses of GC delivered as pulsed i.v. or oral therapy over 1 or 2 weeks are equally effective. Although this study was restricted to just 12 months of follow-up, this is the period of most intense immunosuppression, with the highest conventional doses of GC and the highest treatment-related mortality. During this period we did not observe significant side effects associated with GCs.
A prior study in patients with AAV implicated GC use in the development of damage [14] as recorded by the VDI, which has been shown to be predictive of mortality Our patients were compared with matched patients from (a) the EUVAS studies CYCAZAREM, CYCLOPS and MEPEX (n = 139) and with patients from (b) the RTX arm of the RITUVAS trial (n = 33). Three patients died in the first 12 months, so N=46 at 12 months remission. *P < 0.05, **P < 0.01 and ***P < 0.001. [29, 30] . In keeping with lower GC exposure, our patients at 12 months had very low VDI scores. A review of the adverse events in published EUVAS studies demonstrated that 8.2% of patients developed GC-induced diabetes during the first year after diagnosis [4] . Additionally, 20% of patients have been shown to gain >10 kg of weight, with this weight gain sustained for >12 months [31] . We found no new cases of diabetes but no statistical difference in weight gain compared with the EUVAS and RITUXVAS cohorts. It is important to note that weight gain is often poorly recorded and may also be influenced by renal impairment, fluid retention and dialysis prescription. Patients with AAV report a poorer quality of life compared with the general population, and high GC doses represent a potentially modifiable factor that is related to a poor physical component score when assessing quality of life in AAV patients [32] . This is not just due to disease activity affecting quality of life and necessitating the use of GCs, but is also likely to be due to the direct effects associated with the GC themselves, such as depression. Therefore strategies that decrease long-term GC exposure could significantly impact on long-term patient morbidity and mortality, which may not be apparent with only 12 months of follow-up.
B cell depletion therapy with RTX may allow for discontinuation of other immunosuppressant agents, including GCs. The RAVE trial aimed to completely stop prednisone by 5.5 months if the patient was in remission. These data demonstrated that RTX was effective in the induction of remission, with a low risk of relapse as long as B cells and ANCA remain undetectable [5, 33] . In addition, regular B cell depletion during maintenance therapy has been used as a strategy that allows the weaning of other immunosuppressant medication [34] .
Importantly, we enrolled patients with severe disease, including some who were dialysis dependent or had pulmonary haemorrhage, all of whom were successfully managed with early GC withdrawal. Compared with standard-of-care treatment as used in previous EUVAS trials, our strategy resulted in similar remission rates without excessive levels of damage or persistent inflammatory markers. However, there are limitations of this study, including its non-randomized design and potential bias for patient selection. Patients were recruited in a small number of expert centres who are likely to have the best outcomes for their patients and thus results may be weaker in a broader-based study. EUVAS trial comparators included data collected up to 22 years ago and improved outcomes for AAV have been reported during this time.
Based on these encouraging pilot data, we propose an international randomized study to compare such a GC minimization regime against the current standard of care as induction treatment in AAV.
